The store will not work correctly in the case when cookies are disabled.
Biological Data
| Biological description | Transglutaminase inhibitor. Shows neuroprotective actions and acts as an antioxidant. Shows actions against Huntington's disease. |
Solubility & Handling
| Storage instructions | room temperature (desiccate) |
| Solubility overview | Soluble in water (100mM) or DMSO (100mM) |
| Important | This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use. |
Chemical Data
| Chemical name | 2,2'-Diaminodiethyl disulfide dihydrochloride |
| Chemical structure | ![Cystamine dihydrochloride [56-17-7] Chemical Structure](data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAAEAAAABCAQAAAC1HAwCAAAAC0lEQVR4nGP6zwAAAgcBApocMXEAAAAASUVORK5CYII= "Cystamine dihydrochloride [56-17-7]") |
| Molecular Formula | C4H12N2S2.2HCl |
| InChiKey | YUFRRMZSSPQMOS-UHFFFAOYSA-N |
References for Cystamine dihydrochloride
References are publications that support the biological activity of the product
-
Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells--protective effect of cystamine and creatine.
Ribeiro M et al (2013) Toxicol Sci 136(2) : 487-99. -
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.
Borrell-Pagès M et al (2006) J Clin Invest 116(5) : 1410-24. -
Cystamine and cysteamine prevent 3-NP-induced mitochondrial depolarization of Huntington's disease knock-in striatal cells.
Mao Z et al (2006) Eur J Neurosci 23(7) : 1701-10. -
Therapeutic effects of cystamine in a murine model of Huntington's disease.
Dedeoglu A et al (2002) J Neurosci 22(20) : 8942-50.
Transglutaminase inhibitor
![Cystamine dihydrochloride [56-17-7] Chemical Structure](https://cdn.hellobio.com/media/catalog/product//h/b/hb0870.png "Cystamine dihydrochloride [56-17-7]")
Understanding purity and quality - a guide for life scientists